With 0.98 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.84 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $28.865 whereas the lowest price it dropped to was $27.2. The 52-week range on EWTX shows that it touched its highest point at $38.12 and its lowest point at $14.90 during that stretch. It currently has a 1-year price target of $47.00. Beta for the stock currently stands at 0.21.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EWTX was up-trending over the past week, with a rise of 1.26%, but this was up by 5.62% over a month. Three-month performance dropped to -15.37% while six-month performance rose 68.36%. The stock gained 58.16% in the past year, while it has gained 5.62% so far this year. A look at the trailing 12-month EPS for EWTX yields -1.49 with Next year EPS estimates of -1.87. For the next quarter, that number is -0.42. This implies an EPS growth rate of 5.75% for this year and -25.86% for next year. EPS is expected to decline by -12.16% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -68.02%.
Float and Shares Shorts:
At present, 94.41 million EWTX shares are outstanding with a float of 62.40 million shares on hand for trading. On 2025-01-15, short shares totaled 6.74 million, which was 711.00004 higher than short shares on 1734048000. In addition to Dr. Peter A. Thompson FACP, M.D. as the firm’s Co-Founder & Independent Chairman, Dr. Kevin Koch Ph.D. serves as its President, CEO & Director.
Institutional Ownership:
Through their ownership of 1.11474 of EWTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, EWTX reported revenue of $0.0 and operating income of -$40432000.0. The EBITDA in the recently reported quarter was -$39830000.0 and diluted EPS was -$0.36.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EWTX since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With EWTX analysts setting a high price target of 56.0 and a low target of 30.0, the average target price over the next 12 months is 47.0. Based on these targets, EWTX could surge 98.58% to reach the target high and rise by 6.38% to reach the target low. Reaching the average price target will result in a growth of 66.67% from current levels.
Analysts have provided yearly estimates in a range of -$1.42758 being high and -$1.61244 being low. For EWTX, this leads to a yearly average estimate of -$1.4892. Based on analyst estimates, the high estimate for the next quarter is -$0.34 and the low estimate is -$0.51. The average estimate for the next quarter is thus -$0.39.
